David G Lowe, Ph.D.
Co-founder, Chairman and Chief Executive Officer
As a scientist, venture capitalist and entrepreneur Dr Lowe’s career has centered on discovery and innovation in life sciences. Most recently Dr. Lowe was an investor, advisor, and Vice Chair of the Board of Shattuck Labs (NASDAQ: STTK), a biotechnology company developing novel bifunctional fusion proteins. As co-founder and CEO of Austin based Aeglea BioTherapeutics (NASDAQ: AGLE), he led the company into clinical trials in oncology and enzyme replacement therapy for genetic rare disease. As a venture capitalist at Skyline Ventures Dr Lowe worked on building and investing in therapeutic, diagnostic, and research tools companies. Starting his career at Genentech Inc., he became a Research Director with responsibility for small molecule and biologic drug discovery programs. Dr Lowe received a BS and PhD in Biochemistry from the University of Toronto, Canada
Everett Stone, Ph.D.
Co-founder and Chief Scientific Officer
Dr Stone is a Research Professor at the University of Texas at Austin and is an experienced cancer biologist and drug developer specializing in enzyme therapeutics for cancer (immuno)therapy and for the treatment of rare genetic diseases. Prior to co-founding Delta Therapeutics Everett scientifically co-founded Aeglea Biotherapeutics and Ikena Oncology who are currently progressing several therapeutic enzymes he (co)invented through Phase I-III clinical trials. He received his B.A. degree from Drury University and his Ph.D. from UT Austin where he was named the “Emerging Inventor of the Year” in 2017 for his translational work.
Danforth Advisors Co-Founder and Managing Director
Daniel Geffken is a proven leader of life science companies with more than 30 years of experience steering strategy, finance and operations across all stages of the corporate life cycle. As a co-founder and Managing Director of Danforth Advisors, he leads a team of more than 130 consultants in strategic CFO advisory, accounting and operational support for over 225 active clients, ranging from life science start-ups to publicly traded companies with $1 billion+ market capitalizations. He has served as CFO or executive-level advisor to numerous companies, including Apellis Pharmaceuticals, Century Therapeutics, Atea, Cidara, Editas Medicine, Elicio Therapeutics, Homology Medicines, Promedior, Elicio Therapeutics and Prilenia.
Over the course of his career, Daniel has raised nearly $2 billion in equity and debt securities for life science companies. Among his pre-Danforth roles, he served as CFO of Transkaryotic Therapies, where he negotiated and closed five equity transactions totaling $600 million – including the largest private placement in biotechnology history at the time. Daniel has been a board member and chairman of audit and compensation committees of both public and private life science companies, including Windtree Therapeutics. He holds a BS from The Wharton School, University of Pennsylvania, and a MBA from Harvard Business School.
Dr. F. Andrew Dorr
Chief Medical Officer
Dr Dorr is a medical oncologist with a long history of successful cancer drug development experience, with leadership participation in the development of Gemzar® (gemcitabine) in pancreatic and non-small cell lung cancers, Treanda® (bendamustine) in chronic lymphocytic leukemia and non-Hodgkin lymphoma as well as Avastin® (bevacizumab) in glioblastoma and Talzenna® (talazoparib) in BRCA mutant breast cancer. Dr. Dorr has had a successful consulting business in cancer drug development since 2005. Previously, he served as Chief Operating Officer at Salmedix Inc. from April 2003 until August 2004. From June 1996 to March 2003, he served as Vice President of oncology drug development at Isis (now Ionis) Pharmaceuticals, Inc. and served as its Chief Medical Officer. He also served as clinical research physician and then medical advisor at Eli Lilly & Company where he was responsible for the strategy for Lilly’s cancer pipeline from pre-clinical through Phase III development. While at the National Cancer Institute, he was responsible for national clinical trial programs in breast, prostate, kidney, bladder and testicular cancers, as well as melanoma. Dr. Dorr has over 60 publications on drug development in books and journals. Dr. Dorr received his B.S. degree from Davidson College and holds his M.D. from the University of North Carolina at Chapel Hill.
Joseph E. Tyler
Vice President of CMC
Mr. Tyler has had over 40 years of experience in the areas of pharmaceutical process development, manufacturing, and CMC drug development management with both large pharmaceutical and smaller biotechnology companies. He received his B.S in Chemical Engineering from Carnegie Mellon University and an M.S. in Biochemical Engineering from Cornell University. Previously he was Vice President CMC for Shattuck Labs and has worked for GelTex Pharmaceuticals, Salix Pharmaceuticals, Momenta Pharmaceuticals, Proteon Therapeutics, KBI BioPharma, and Aeglea Biotherapeutics. Mr. Tyler has managed the chemistry, manufacturing, and controls development programs and ultimate approval of five new drugs.
Erin Overstreet Ph.D.
Vice President of Operations and Corporate Development
With over 14 years of experience working with early-stage technologies and companies, at both the University of California San Francisco and UT Austin, Dr. Overstreet has licensed over 200 technologies and helped to form over 40 startups, which have collectively been financed by VCs to over $500M, with 3 IPOs. She has broad experience in commercializing early-stage technologies, focusing and refining inventions, protecting key IP, marketing to industry partners, and negotiating deals that mature the technology and satisfy stakeholders. Most recently, Dr. Overstreet was Director of Licensing at the UT Austin Office of Technology Commercialization. In this role, she led a team of licensing professionals to protect and commercialize intellectual property covering early-stage technologies across all industries. Her leadership led to record-breaking numbers of IP licenses and start-ups formed. Dr. Overstreet holds a PhD in Molecular Biology from the University of Texas at Austin.